



# WHATS NEW FROM ESMO<sup>2021</sup>?



**18<sup>TH</sup> - 19<sup>TH</sup>  
DECEMBER 2021**

**SATURDAY & SUNDAY**

**Time: 18:30 - 21:30**

**ORGANIZING SECRETARY**



**Dr. Sushant Mittal**

Consultant Medical Oncologist,  
Action Cancer Hospital, Delhi

Click the link below to register

<https://www.riverroute.in/sparssh-esmo2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

# WHATS NEW FROM ESMO 2021?



**18<sup>TH</sup> - 19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30**

## WELCOME ADDRESS

Dear Colleagues,

On behalf of Sparssh we invite you for an enlightening update titled **“Whats new from ESMO 2021”** to be held on **Saturday 18<sup>th</sup> & Sunday 19<sup>th</sup> December 2021** on virtual Platform.

The ESMO Congress has always offered the stage for promising developments to be presented to the oncology community, looking beyond for the development of new agents, both for biomarker-driven and agnostic approach, but also to improve the management of resistance after molecular or immune treatments. Discussing the learnings of these prospects from an Indian context will help us in our the quest to significantly improve the survival and quality of life of our patients.

As personalised medicine has come of age, an ever-increasing number of genetic alterations in cancer cells are being identified as potential targets for novel therapies. Thanks to the increasingly widespread use of broad genetic testing and next-generation sequencing, drugs we know in oncology are now finding new potential applications: including the rare group which has no approved treatment options to date. Delivering anticancer agents straight to the core of the tumour cell with ADCs, and expanded horizons in immunotherapy with new combinations are some of the newer concepts presented at esmo which is important for us to discuss.

We have shortlisted some noteworthy data from ESMO to be discussed at this meeting which will cover all the major tumor types. Leading national faculty will throw light on the use of this new information in day to day practice. We expect around 300 delegates to be present at this meeting.

For our industry participation we have planned various scientific engagement and branding opportunities towards sponsorship.

We look forward to your participation in making this into a meaningful program.

Regards

**Dr. Sushant Mittal**  
Consultant Medical Oncologist,  
Action Cancer Hospital, Delhi

**Dr. Samit Purohit**  
Consultant Medical Oncologist,  
Action Cancer Hospital, Delhi

Click the link below to register  
<https://www.riverroute.in/sparssh-esmo2021>

Virtual Webinar Managed by  
**riverroute**  
Leaders in Streaming Modules



# WHATS NEW FROM ESMO 2021?



18<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

## SCIENTIFIC PROGRAM | DAY 1

### Session 1 : Breast Cancer

#### Supported by Novartis

18:30 – 18:45

Consistently Superior OS in HR+HER2- aBC  
Speaker: Dr. Peush Bajpai

18:45 – 19:00

PIKing the right strategy in Management of  
HR+HER- aBC  
Speaker: Dr. Mohit Agarwal

#### Supported by Lilly

19:00 – 19:40

Cancer does not take a day off then why should  
a CDK 4/6 inhibitor?

20 Mins

- Clinical Case presentation – Why I chose Abemaciclib for my HR+/HER2- MBC patient with Poor Prognostic Factors  
Moderator : Dr. Adwait Gore
- Q&A - “Tailoring treatment in HR+ HER2- MBC based on the prognostic factors”  
Experts :  
Dr. Randeep Singh | Dr. Shirish Alurkar  
Dr. Bharat Vaswani | Dr. Ravi Wategaonkar

20 Mins

- Clinical Case presentation – Why I chose Abemaciclib for my HR+/HER2- MBC patient with Poor Prognostic Factors  
Moderator : Dr. Bharat Vaswani
- Q&A - “Tailoring treatment in HR+ HER2- MBC based on the prognostic factors”  
Experts :  
Dr. Randeep Singh | Dr. Shirish Alurkar  
Dr. Adwait Gore | Dr. Ravi Wategaonkar

#### Supported by Dr. Reddy's

19:40 – 19:55

Role of Triptorelin in Early Breast Cancer  
Speaker : Dr. Punkaj Goyal

Click the link below to register

<https://www.riverroute.in/sparssh-esmo2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

# WHATS NEW FROM ESMO 2021?



18<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

## SCIENTIFIC PROGRAM | DAY 1

### Supported by Pfizer

19:55 - 20:15

Navigating Management with CDK 4/6 inhibitors : From Clinical Trials to Clinical Practice  
Speaker : Dr. Devavrat Arya

### Session 2 : Renal Cell Carcinoma (RCC)

### Supported by Industry Symposium

20:15 - 20:30

5-year follow-up : CheckMate 214  
Speaker: Dr. Samit Purohit

### Session 3 : Hepatocellular Carcinoma (HCC)

### Supported by Roche

20:30 - 20:50

Immunotherapy combination in management of Unresectable Hepatocellular carcinoma  
Speaker: Dr. Vineet Talwar

### Session 4 : Lung Cancer

### Supported by AstraZeneca

20:50 - 21:00

Experience sharing on Durvalumab in ES-SCLC  
Speaker : Brig. Rajeshwar Singh

21:00 - 21:10

Newer paradigm in the treatment of Resected EGFRm NSCLC  
Speaker : Dr. Ullas Batra

21:10 - 21:20

Management of 1st line Ca Ovary - Bringing Precision to Medicine"  
Speaker : Dr. Manish Singhal

21:20 - 21:30

Q & A With discussion

21:30

Closing Remarks

Click the link below to register

<https://www.riverroute.in/sparssh-esmo2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules

# WHATS NEW FROM ESMO 2021?



19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

## SCIENTIFIC PROGRAM | DAY 2

### Session 5 : Prostate Cancer

**Supported by Lupin**

18:30 - 18:45

CHECKMATE 9 KD - rucaparib + nivolumab in Prostate Cancer  
Speaker: Dr. Kumar Deep

### Session 6 : Gastric Cancer

**Supported by Lilly**

18:45 - 19:05

Clinical case based discussion of an **advanced Gastric Cancer** patient  
Moderator: Dr. Prasad Narayanan  
Experts: Dr. Anita Ramesh | Dr. Rahul Sud

### Session 7 : Lung Cancer

19:05 - 19:25

Clinical case based discussion: Does one size fit all? What information will help improve our treatment decisions in **EGFRm+ advanced NSCLC**?  
Moderator: Dr. Ghanashyam Biswas  
Experts: Dr. Chandrakanth M.V. | Dr. S.S. Nirni

**Supported by Novartis**

19:25 - 19:40

CAPMATINIB: unlocking the unmet need in MET ex14 skipping NSCLC  
Speaker: Dr. Manish Singhal

19:40 - 19:55

Personalized therapy to further improve outcomes in patients with BRAF mutated mNSCLC  
Speaker: Dr. Chandragouda

**Supported by Pfizer**

19:55 - 20:15

First line treatment of ALK rearranged NSCLC  
Speaker: Dr. Rajat Bajaj

20:15 - 20:35

Exon 19 deletion and exon 21 L858R substitution mutation: Are they same?  
Speaker: Dr. Chaturbhuja Agrawal

Click the link below to register

<https://www.riverroute.in/sparssh-esmo2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules



# WHATS NEW FROM ESMO<sup>2021</sup>?



19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

## SCIENTIFIC PROGRAM | DAY 2

### Supported by Roche

20:35 - 20:55 Atezolizumab in 1st line mNSCLC (IMPOWER 110/130/150)  
Speaker: Dr. Shyam Aggarwal

### Supported by ESAI

21:55 - 21:05 2nd line treatment options in advance RCC  
Speaker: Dr. Sushant Mittal

21:05 - 21:30 Concluding Remarks

Click the link below to register  
<https://www.riverroute.in/sparssh-esmo2021>

Virtual Webinar Managed by  
**riverroute**  
Leaders in Streaming Modules

# WHATS NEW FROM ESMO 2021?



18<sup>TH</sup> - 19<sup>TH</sup> DECEMBER 2021 | 18:30 - 21:30

VIRTUAL EVENT MANAGED BY

## riverroute®

▣ Leaders in Streaming Modules

**Sarika Barne**

Webinar Manager,  
River Route Event, Mumbai

Mobile: +91 99301 94266 | E-mail : rrcgsarika@gmail.com

Click the link below to register

<https://www.riverroute.in/sparssh-esmo2021>